Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis
- 69 Downloads
The study aims to evaluate the therapeutic effects of dermatologic tacrolimus ointment on eyelids to treat refractory vernal keratoconjunctivitis (VKC).
This institutional study examined the effects of steroid treatment for 10 patients diagnosed with severe VKC refractory to steroid treatment. Patients received 0.1% dermatologic topical tacrolimus treatment on their eyelids once or twice daily for concomitant atopic dermatitis. The therapeutic outcomes were evaluated according to change in severity of clinical findings recorded with serial external ocular photography and change in requirement for steroid treatment.
Clinical signs and symptoms improved substantially after tacrolimus treatment. Significant reduction in size of papillae, decrease of discharge, improvement in hyperemia, and shield ulcer healing with re-epithelization were observed in all patients. Six out of 10 (60%) patients did not receive steroid treatment. Long-term maintenance of tacrolimus was required to prevent episodic exacerbation. Patients’ only treatment-related complaints were of mild burning sensations during medication application to eyelids, and this sensation disappeared a few days after treatment.
Application of 0.1% dermatologic tacrolimus ointment to eyelids is effective and safe in the treatment of refractory VKC in patients with concomitant atopic dermatitis. This treatment may serve as a substitute for or decrease the requirement of steroid treatment.
KeywordsVernal keratoconjunctivitis Steroid Dermatologic tacrolimus ointment Eyelid
This study received no funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not present any studies with animals performed by any of the authors.
Informed consent was obtained from all participants included in the study.
- 4.Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, Kumagai N, Satake Y, Shoji J, Nakagawa Y, Namba K, Fukagawa K, Fukushima A, Fujishima H, Japanese Society of A (2017) Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 66:220–229. https://doi.org/10.1016/j.alit.2016.12.004 CrossRefGoogle Scholar
- 18.De Smedt S, Nkurikiye J, Fonteyne Y, Tuft S, De Bacquer D, Gilbert C, Kestelyn P (2012) Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial. Br J Ophthalmol 96:323–328. https://doi.org/10.1136/bjophthalmol-2011-300415 CrossRefGoogle Scholar
- 19.Spadavecchia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, Bellizzi M, Rizzo G, Procoli U, Bellizzi G, Armenio L (2006) Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 17:527–532. https://doi.org/10.1111/j.1399-3038.2006.00427.x CrossRefGoogle Scholar
- 22.Pucci N, Caputo R, di Grande L, de Libero C, Mori F, Barni S, di Simone L, Calvani A, Rusconi F, Novembre E (2015) Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: a randomized, comparative, double-blind, crossover study. Pediatr Allergy Immunol 26:256–261. https://doi.org/10.1111/pai.12360 CrossRefGoogle Scholar
- 23.Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N, Shoji J, Takamura E, Nakagawa Y, Namba K, Fujishima H, Miyazaki D (2014) Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol 98:1023–1027. https://doi.org/10.1136/bjophthalmol-2013-304453 CrossRefGoogle Scholar
- 25.Tanaka M, Dogru M, Takano Y, Miyake-Kashima M, Asano-Kato N, Fukagawa K, Tsubota K, Fujishima H (2006) Quantitative evaluation of the early changes in ocular surface inflammation following MMC-aided papillary resection in severe allergic patients with corneal complications. Cornea 25:281–285. https://doi.org/10.1097/01.ico.0000183533.14899.8d CrossRefGoogle Scholar
- 26.Ganong WF (2005) Review of medical physiology (LANGE basic science) 22nd Edition. McGraw-Hill Medical, New York CityGoogle Scholar
- 29.FDA U (2000) US FDA advisory committee recommends approval of tacrolimus ointment. Skin Therapy Lett 6:5Google Scholar
- 32.Mandelin JM, Remitz A, Virtanen HM, Malmberg LP, Haahtela T, Reitamo S (2010) A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatol Treat 21:167–170. https://doi.org/10.3109/09546630903493329 CrossRefGoogle Scholar
- 36.Miyazaki D, Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Shoji J, Takamura E, Nakagawa Y, Namba K, Fujishima H (2017) Steroid-sparing effect of 0.1% tacrolimus eye drop for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases. Ophthalmology 124:287–294. https://doi.org/10.1016/j.ophtha.2016.11.002 CrossRefGoogle Scholar